Scientists working on NASA's Nancy Grace Roman Space Telescope have achieved a significant milestone in assembling the next-generation observatory, which aims to address critical questions about dark matter, exoplanets and infrared astrophysics. The Optical Telescope Assembly, a key component of the Nancy Grace Roman Space Telescope , or Roman for short, was successfully delivered to NASA's Goddard Space Flight Center in Greenbelt, Maryland, in early November from Rochester, New York, where it was designed and built by the company L3Harris Technologies. This advanced assembly includes a state-of-the-art primary mirror, designed to capture and focus faint infrared light from the distant cosmos, as well as nine additional precision-engineered mirrors. Together with its structural supports and sophisticated electronics, the assembly will serve as the telescope's "eye," enabling groundbreaking observations and unlocking the mysteries of the universe . The delivery marks a crucial step toward completing the Roman Space Telescope, which is expected to expand our understanding of the cosmos and revolutionize the study of dark energy , galaxy formation , and planetary systems beyond our solar system . Related: What is the Nancy Grace Roman Space Telescope? "Projects of this magnitude demand excellence in virtually every aspect," J. Scott Smith, the assembly's telescope manager at NASA Goddard, told Space.com via email. "This drive for perfection is intensified when building and delivering a space telescope that pushes engineering boundaries to answer seemingly impossible scientific questions." Roman will surpass its predecessor, the Hubble Space Telescope , with its advanced capabilities for conducting large-scale sky surveys. "Much like a cell phone has multiple cameras to capture a wide angle and zoomed image, Webb and Roman will work together to explore our universe with different views," said Smith, referring to NASA's $10 billion James Webb Space Telescope , which launched in December 2021. "Roman's technology and scientific capabilities will also serve as the next critical step towards the Habitable Worlds Observatory , which would enhance our understanding of the universe even further and advance the search for planets that could support life." Equipped with a Wide Field Instrument featuring a 300-megapixel infrared camera, Roman will cover a much broader area of the night sky . Additionally, the telescope is designed to operate at extremely low temperatures, minimizing internal noise and making it easier to detect faint, distant objects. "The wide field of view allows the Observatory to collect in a single image what would take Hubble several hundred, and after accounting for how fast the Roman Observatory can point to a new target, it further improves the efficiency," explained Smith. "One of Roman's main survey campaigns, the High Latitude Wide Area Survey, will cover 2,000 square degrees (about 5% of the sky) in just over seven months. It would take Hubble or Webb hundreds of years to image such a large sky area." The telescope's coronagraph , which has already been installed , will allow it to block out the bright light from stars , enabling direct observation of faint objects like exoplanets and distant galaxies with greater clarity. The design and performance of the assembly will play a crucial role in determining the quality of the mission's results, making the manufacturing and testing processes exceptionally rigorous. Achieving success in such a complex project requires flawless alignment of countless elements, despite the inevitable challenges that arise. "Success requires millions of elements to align perfectly, yet the work is executed by people and machines — both inherently imperfect," Smith said. "Human error, accidents, and mechanical failures are inevitable realities we must contend with. [But] it's not just about preventing mistakes, but about how we respond and recover when they occur. This is where our team truly excelled." To minimize the likelihood of error, each individual component was meticulously tested before assembly. The entire telescope was then subjected to rigorous tests designed to simulate the intense shaking and vibrations it will endure during launch, ensuring it arrives in its desired orbit intact and functions as intended. NASA reports that the telescope underwent a month-long thermal vacuum test to ensure it will withstand the temperature and pressure environment of space , while maintaining its own temperature to within a fraction of a degree. This means the telescope will be able to maintain a stable focus to capture its high-resolution images. This careful coordination and extensive testing is key to ensuring the telescope's performance, especially when it comes to stability. "The Roman telescope represents the pinnacle of telescope stability, a claim substantiated by extensive ground-based testing," Smith added. "To achieve this unprecedented level of stability, we pioneered innovative methods in hardware construction and testing, significantly advancing the state of the art in telescope engineering." Related: NASA's Roman space telescope gets ready to stare at distant suns to find alien planets The next steps involve integrating the optical assembly into Roman's instrument carrier, the structural skeleton of the observatory. According to the team, they remain on track for the telescope's highly anticipated launch in early 2027, atop a SpaceX Falcon Heavy rocket. "A high point of our journey [has been] witnessing the entire telescope come together as an aligned system — a moment that crystallized years of dedication from hundreds of individuals," Smith said. "During this process, the alignment team experienced something truly extraordinary: They were able to look through the telescope in double-pass and see their own reflection. Double-pass is kind of like taking a selfie in a mirror, where you use the telescope to look at itself. "When I had the opportunity to look through the telescope myself, it was nothing short of a transcendent experience," he continued. "Observing the technician re-imaged with such incredible precision and clarity, reduced to just a few inches in size, was surreal. It was a moment that not only showcased the telescope's extraordinary capabilities but also connected us viscerally to the magnitude of our achievement. This experience went beyond mere scientific accomplishment — it touched upon the very essence of human curiosity and our relentless pursuit to understand the cosmos."With favourites out MLS playoffs promise more upsetsDaily Post Nigeria Police nab notorious suspected kidnapper in Kwara Home News Politics Metro Entertainment Sport Metro Police nab notorious suspected kidnapper in Kwara Published on December 12, 2024 By Abdulrazaq Adebayo The Kwara State Police Command has arrested a suspected kidnapper, identified as Mohammed Bello. According to a statement in Ilorin on Thursday by the spokesperson of the command, DSP Ejire Adeyemi Toun, the alleged suspect is also known as “Dandolo.” The spokesperson disclosed: “The arrest was made possible following actionable intelligence received from Egbe, Kogi State, indicating that the suspect had fled to Patigi, Kwara State, to evade arrest.” “Mohammed Bello is suspected to be involved in a series of kidnapping operations in Egbe, Isanlu, and surrounding areas in Kogi State.” “Upon receiving the information, the command immediately deployed a surveillance team to track the suspect’s movements. A thorough search of various locations, including hotels in Patigi, was conducted. Eventually, the suspect was apprehended at an undisclosed location.” The statement added: “The operation was carried out in collaboration with the Nigerian Army Forward Operation Base, FOB, in Egbe, Kogi State, led by Lieutenant Isah. The suspect has been transferred to the Anti-Kidnapping Unit of the State Criminal Investigation Department, SCID, in Ilorin for further investigation. “Mohammed Bello has confessed to several kidnapping incidents along the Omu-Aran-Ilofa-Osi-Eruku-Egbe road in Kwara State and also to kidnapping incidents along the Lagos-Ibadan Expressway.” Kwara State Commissioner of Police, Victor Olaiya, assured the public that a discreet and thorough investigation will be conducted to ensure that justice is served, asserting that the command remains committed to ensuring the safety and security of all residents in Kwara State and its environs. The command extended its appreciation to members of the public and security partners for their cooperation and swift action on the matter and encouraged citizens to continue providing timely information to assist in combating crime. Related Topics: kidnapper Kwara police Don't Miss Court remands woman for allegedly killing daughter with rat poison You may like Murder trial of suspects in Police Inspector’s death faces setback Police arrest 8 ‘one chance’ suspects in FCT, recover 7 vehicles Police demolish Ibom Youth Council headquarters, arrest three suspects Ogun gets new Commissioner of Police Police arrest two suspects, recover 25 stolen phones in Borno Court halts publication, sale of Farotimi’s book, orders Police, DSS to seize copies Advertise About Us Contact Us Privacy-Policy Terms Copyright © Daily Post Media Ltdjili games tricks 。

MENLO PARK, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Sight Sciences , Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced the results of a Budget Impact Analysis (“BIA”) of the TearCare ® System (“TearCare”) for the treatment of MGD-associated dry eye disease (“DED”) in the United States. A BIA estimates the fiscal impact of adopting a new technology or treatment within a specific provider environment or patient population – in this case, identifying the health savings associated with increased adoption of TearCare as compared to prescription dry eye medications for patients with DED.* The analysis, projected over a two-year period, focused on moderate to severe MGD- associated DED in U.S. patients over 18 years of age. It compared the financial impact of TearCare to commonly prescribed dry eye medications, including Restasis 0.05% branded and generic, and Xiidra 5%. Key findings indicated that a 20% increase in market share of TearCare compared to prescription dry eye medications would yield an estimated annual savings of $36.87 per member per year (“PMPY”) in a hypothetical health plan with one million covered lives. The study showed a direct relationship between increased utilization of TearCare in place of prescription medications and total costs savings from a US payer perspective. “In addition to the strong clinical efficacy of TearCare shown in the SAHARA and OLYMPIA randomized controlled trials, this budget impact analysis reported that increased adoption of TearCare treatments for patients with MGD-associated DED was estimated to result in meaningful cost savings. We believe the combination of the strong clinical data from the SAHARA RCT and the findings of this budget impact analysis create a compelling case for payors to cover treatments performed with TearCare at an appropriate reimbursement level,” said Paul Badawi, Co-Founder and Chief Executive Officer of Sight Sciences. “Pioneering market access to interventional dry eye treatments with TearCare on behalf of patients and the eye care providers who care for them is a core component of our strategy and this milestone represents progress towards delivering this innovative technology to a portion of the 17.9 million patients diagnosed with dry eye disease in the U.S.” Authors and affiliations : Phoenix Riley, PharmD, MSc (AESARA, Inc.); Cristina Masseria, PhD (AESARA, Inc.); Chad Patel, PharmD (AESARA, Inc.); Roberta Longo, PhD (AESARA, Inc.); Lorie Mody, PharmD (AESARA, Inc.), and Thomas Chester, OD, FAAO (Cleveland Eye Clinic). *The BIA was developed in accordance with established ISPOR guidelines, but it was based upon various assumptions, including with respect to cost of treatments, respective usage and market uptake of prescription drops and TearCare, efficacy (including duration of effect), safety and similar factors. These assumptions may not be consistent with actual clinical and market conditions, and changes in one or more of these assumptions could cause individual health plan results to differ. Paper Reference: Chester, T., Longo, R., Masseria, C., Riley, P., Patel, C., & Mody, L. (2024). Budget impact analysis (BIA) of the TearCare System for the treatment of meibomian gland dysfunction (MGD)-associated dry eye disease (DED) in the United States (US). Expert Review of Ophthalmology , DOI: 10.1080/17469899.2024.2444930. About Sight Sciences Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI ® Surgical System is an implant-free glaucoma surgery technology (i) indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and (ii) CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world’s leading cause of irreversible blindness. The Company’s SION ® Surgical Instrument is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s TearCare System technology is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to Meibomian Gland Disease (“MGD”) when used in conjunction with manual expression of the meibomian glands, enabling clearance of gland obstructions by eyecare providers to address the leading cause of dry eye disease. For more information, visit www.sightsciences.com . Sight Sciences, the Sight Sciences logo, TearCare, SmartHub and SmartLids are trademarks of Sight Sciences registered in the United States. OMNI and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories. © 2024 Sight Sciences. All rights reserved. Forward-Looking Statements This press release, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and includes this statement for purposes of complying with these safe harbor provisions. Any statements made in this press release that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include, without limitation statements regarding estimated costs savings associated with use of the TearCare System; and the belief that the findings of this budget impact analysis create a compelling case for payors to cover treatments performed with TearCare at an appropriate reimbursement level. These statements often include words such as “anticipate,” “expect,” “suggests,” “plan,” “believe,” “intend,” “estimates,” “targets,” “projects,” “should,” “could,” “would,” “may,” “will,” “forecast” and other similar expressions. We base these forward-looking statements on our current expectations, plans and assumptions that we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances at such time. Although we believe that these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our business, results of operations and financial condition and could cause actual results to differ materially from those expressed in the forward-looking statements. These forward-looking statements are subject to and involve numerous risks, uncertainties and assumptions, including those discussed under the caption “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, as may be updated from time to time in subsequent filings, and you should not place undue reliance on these statements. These cautionary statements are made only as of the date of this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Media contact pr@SightSciences.com Investor contact: Philip Taylor Gilmartin Group 415.937.5406 Investor.Relations@Sightsciences.com

Ohio State, Michigan players involved in melee after Buckeyes loss, multiple people pepper sprayed

Carlsquare Logo (PRNewsfoto/Carlsquare, LLC) SAN FRANCISCO , Dec. 19, 2024 /PRNewswire/ -- Carlsquare announced its role as exclusive financial advisor to Boomi, the intelligent integration and automation leader jointly owned by Francisco Partners and TPG, on its acquisition of Rivery, an advanced data integration provider offering cutting-edge Change Data Capture (CDC) for real-time, efficient data movement. Founded with a mission to streamline data management, Rivery enables organizations to deploy data pipelines efficiently by utilizing ELT capabilities. With its innovative solutions, Rivery has established itself as a leader in simplifying data management through real-time data integration and advanced CDC technology. The acquisition represents a significant milestone for Boomi as it accelerates its vision to simplify data management, allowing customers to consolidate on fewer vendors and address evolving data management needs in the age of data-driven decision-making and AI. "This acquisition marks an important milestone for Boomi as we expand our platform to address the evolving data management needs of businesses in the age of data-driven decision-making and AI. Carlsquare's expertise and dedication through the entire process was a critical success element. Their deep understanding of the automation and data sectors enabled them to be true champions of our success," said Steve Lucas , Chairman and CEO of Boomi. Susan Blanco , Managing Partner at Carlsquare, added, "Boomi's acquisition of Rivery underscores the growing importance of advanced data integration solutions. We are proud to have delivered an exceptional outcome for Boomi and its stakeholders as they continue to lead in the intelligent integration and automation space." About Boomi: Boomi is the intelligent integration and automation leader, helping organizations around the world streamline critical processes to achieve business outcomes faster. The Boomi Enterprise Platform harnesses advanced AI capabilities to seamlessly connect systems and manage data flows with API management, integration, data management, and AI orchestration in one comprehensive solution. For more information, visit www.boomi.com . About Carlsquare: Carlsquare is a global technology investment bank with over 20 years of experience advising companies and their shareholders on M&A, capital markets, and strategic matters. With 170+ bankers across 8 countries, Carlsquare provides unparalleled access to investors, private equity partners, and strategic buyers. For more information, visit www.carlsquare.com . View original content to download multimedia: https://www.prnewswire.com/news-releases/carlsquare-advises-boomi-on-acquisition-of-data-integration-provider-rivery-302336746.html SOURCE Carlsquare, LLC

AFTER their bitter 15-year feud, you might expect Noel and Liam Gallagher's mum to be delighted that her sons are on speaking terms again. But Noel has revealed that 81-year-old Peggy “couldn’t give a s**t” that he and his brother have reconciled for their Oasis reunion tour next year. The Don’t Look Back In Anger singer says his mum, who was born in County Mayo in Ireland , was indifferent to her boys finally burying the hatchet. Noel added: “My mum couldn’t give a s**t. My mum never gave a s**t, never. You know what Irish mums are like? "When we told her we were getting back together, she said, ‘Sure, that will be nice’. That was it.” Even so, Noel said he and Liam are determined to get her to one of their gigs next year, and added: “We’ll try and get her to Dublin .” READ MORE ON OASIS Although her sons have a net worth of £58million, Peggy still lives in the modest Manchester council house where she brought up her three children. Speaking at the National Portrait Gallery for the Zoe Law Legends exhibition, he said: “People get f***ing shot up the road and she still leaves the door open.” Now that the brothers are both in their fifties, Noel said neither of them plans to go wild on their tour, after their infamous Wembley gig in 2000 was labelled a “low point” — with Liam drinking on stage and singing the wrong lyrics. Noel said: “No, it won’t be as raucous as back in the day, because we’re on the wrong side of 50 now, so we’re too old. “We’re too old to give a s**t now, so there won’t be any fallouts, there won’t be any fighting. It’s a lap of honour for the band.” Most read in Bizarre Asked if they have been getting in shape for the tour — which is expected to bank them £400million — he added: “Well, I still drink, and I think Liam still drinks.” He did not rule out adding extra dates to the sold-out tour after fans slammed the band for dynamic pricing , which sees the cost of tickets rise in relation to demand, with some being quoted more than £350. So is he happy to have healed his long-running feud? “Of course, yes,” he said. Seems the brothers are back in business. NOEL GALLAGHER has registered a new song in recent weeks, which is bound to set tongues wagging. The rocker logged Leave This City on music database ASCAP, which comes amid repeated insistence from Oasis’s team they have “no plans” to release new music. An insider said: “We know Noel has been in the studio for the last few months making his own music, so it’s possible he and Liam could put out a single.” Come on, lads, give the fans what they want. Taylor turns gridiron to hot TAYLOR SWIFT is one red-hot cheerleader as she steps out to watch boyfriend Travis Kelce in American football gridiron action. She looked festive in a Louis Vuitton zipped jumper and platform boots, cheering and celebrating in the stands as Kelce’s Kansas City Chiefs narrowly defeated the Las Vegas Raiders. Taylor’s dad Scott and Travis’s mum Donna were also with the hitmaker at the Black Friday game and joined in the whooping and hollering. But Taylor will be quickly back to work as she wraps up her Eras Tour next week in Vancouver, Canada . I am sure Travis will return the favour and be right there cheering her on along with her army of fans. Pretty penny for Elsa ELSA HOSK is the latest celebrity to sign with online fashion retailer Pretty Little Thing in a six-figure deal. The Swedish Victoria’s Secret Angel follows in the footsteps of model Naomi Campbell , who released a range with the brand last year. A pal of Elsa’s tells me: “PLT is going more high end, focusing on quality and raising the game in the style world. “Her shoot will drop in the next few weeks in time for Christmas , with vintage vibes and faux fur.” Sounds festive . . . SHE sang about buying her own flowers after her split with actor Liam Hemsworth, but now Miley Cyrus is getting romance and more from boyfriend Maxx Morando. Her musician lover, who she was first linked to in 2022, has been helping her with new album Something Beautiful, set for release next year. Miley said: “I am so honest and open in this album. It made it easier working with somebody who I love.” Fatboy robbed before gig FATBOY SLIM has revealed he was robbed at London’s Euston station. The DJ told on social media how the drama unfolded as he was on his way to the Drumsheds venue in Tottenham, North London, to play a gig. A source said: “Fatboy managed to make it to the event and reported the incident to police. “He was undeniably shaken by the incident but was more concerned that he would let down fans that had turned up to see him.” Fatboy, whose real name is Norman Cook, replied to the event’s creative producer Hannah Ford on Instagram after she posted a collection of pictures of artwork that had transformed the venue for the sold-out event. He replied: “Thank you so much for your hard work and creativity. “So gutted I didn’t get a chance to check out your work (we got robbed at Euston station on our way there . . . )” Fatboy, who was married to Radio 2 star Zoe Ball until 2020, is set to play at the Faena Theater in Miami, Florida , on Tuesday as part of his new tour. It follows the release of his single Bus Stop Please with Daniel Steinberg on his own label, Southern Fried Records. Ncuti's Wilde time on stage WITH a missing handbag and a mischievously camp sub-plot, The Importance Of Being Earnest at the National Theatre felt like a drop of sunshine under the grey skies of London on Thursday night. Sex Education star Ncuti Gatwa takes one of the lead roles in this joyful version of Oscar Wilde’s 1895 farce, which centres on two friends, Algernon Moncrieff and Jack Worthing. As young, eligible bachelors, they both adopt different personas to escape the confines of society and impress the ladies. Jack, played by Mamma Mia! star Hugh Skinner , goes by Earnest when he’s out in the city, while cross-dressing Algernon, played by Ncuti, also uses the same fake name for his alter-ego. The opening scene sees Ncuti dancing in a pink gown and playing the piano at a raucous party – a world away from Algernon’s usual life as an upper-class gentleman in London. But his and Jack’s double lives come undone when they both fall in love under their pretend names. The climax comes as Jack, who was found as a baby in a handbag at London’s Victoria station, appears on top of the stage’s curtain with the very same bag to prove his real identity. I only wish I had lost my own bag so I can return to watch this brilliant adaptation again. Bandit eyeing Glasto CLEAN BANDIT have revealed they are set to play Glastonbury next year. The electronic music trio have performed at Worthy Farm three times previously, but are now eyeing a triumphant return to the festival. Cellist Grace Chatto said: “We are hoping to be on that line-up, it’s looking likely. “We’re ready to go back, as we last played seven years ago in 2017. “It’s time – we love the vibe there and it’s so fun getting to meet so many of our fans.” READ MORE SUN STORIES Grace also teased that the band have an exciting collaboration with a huge American artist possibly lined up to happen next year. She added: “It’s an amazing singer from across the Pond – but it’s too soon to say just in case we don’t pull it off.” THE RCA Sony Music Christmas Showcase at Stereo, Covent Garden, central London, Tuesday. WHO WAS THERE: Cat Burns, Sasha Keable, Louis Dunford and Ossi Grace. WHAT WE ATE: Mini hash browns, smoked salmon canapes and mini fish fingers. WHAT WE DRANK: Margarita and Paloma cocktails along with champagne. This week who would I... Avoid Marry AvoidINCLINE VILLAGE, Nev., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Tri Pointe Homes, Inc. (the “Company”) (NYSE:TPH) today announced that its Board of Directors has approved a new stock repurchase program authorizing the repurchase of up to $250 million of common stock through December 31, 2025 (the “Repurchase Program”), which succeeds the stock repurchase program that the Board of Directors authorized in December 2023 (the “2024 Repurchase Program”). For the fourth quarter through December 17, 2024, under the 2024 Repurchase Program, the Company repurchased 1,202,913 shares of common stock at a weighted average price per share of $41.57 for an aggregate dollar amount of $50.0 million. For the full year through December 17, 2024, under the 2024 Repurchase Program, the Company repurchased 3,964,537 shares of common stock at a weighted average price per share of $36.97 for an aggregate dollar amount of $146.6 million. Purchases of common stock pursuant to the Repurchase Program may be made in open market transactions effected through a broker-dealer at prevailing market prices, in block trades, or by other means in accordance with federal securities laws, including pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The Company is not obligated under the Repurchase Program to repurchase any specific number or dollar amount of shares of common stock, and it may modify, suspend, or discontinue the Repurchase Program at any time. Company management will determine the timing and amount of any repurchases in its discretion based on a variety of factors, such as the market price of the Company’s common stock, corporate requirements, general market economic conditions, legal requirements, and applicable tax effects. About Tri Pointe Homes® One of the largest homebuilders in the U.S., Tri Pointe Homes, Inc. (NYSE: TPH) is a publicly traded company operating in 12 states and the District of Columbia, and is a recognized leader in customer experience, innovative design, and environmentally responsible business practices. The company builds premium homes and communities with deep ties to the communities it serves—some for as long as a century. Tri Pointe Homes combines the financial resources, technology platforms and proven leadership of a national organization with the regional insights, longstanding community connections and agility of empowered local teams. Tri Pointe has won multiple Builder of the Year awards, was named to the 2024 Fortune World’s Most Admired CompaniesTM list, is one of the 2023 Fortune 100 Best Companies to Work For® and was designated as one of the PEOPLE Companies That Care® in 2023 and 2024. The company was also named as a Great Place To Work-CertifiedTM company for four years in a row (2021 through 2024), and was named on several Great Place to Work ® Best Workplaces lists (2022 through 2024). For more information, please visit TriPointeHomes.com . Forward-Looking Statements Various statements contained in this press release, including those that express a belief, expectation or intention, as well as those that are not statements of historical fact, are forward-looking statements. These forward-looking statements may include, but are not limited to, statements regarding our strategy, projections and estimates concerning the timing and success of specific projects and our future production, land and lot sales, operational and financial results, including our estimates for growth, financial condition, sales prices, prospects, and capital spending. Forward-looking statements that are included in this press release are generally accompanied by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “future,” “goal,” “guidance,” “intend,” “likely,” “may,” “might,” “outlook,” “plan,” “potential,” “predict,” “project,” “should,” “strategy,” “target,” “will,” “would,” or other words that convey future events or outcomes. The forward-looking statements in this press release speak only as of the date of this press release, and we disclaim any obligation to update these statements unless required by law, and we caution you not to rely on them unduly. These forward-looking statements are inherently subject to significant business, economic, competitive, regulatory and other risks, contingencies and uncertainties, most of which are difficult to predict and many of which are beyond our control. The following factors, among others, may cause our actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements: the effects of general economic conditions, including employment rates, housing starts, interest rate levels, home affordability, inflation, consumer sentiment, availability of financing for home mortgages and strength of the U.S. dollar; market demand for our products, which is related to the strength of the various U.S. business segments and U.S. and international economic conditions; the availability of desirable and reasonably priced land and our ability to control, purchase, hold and develop such parcels; access to adequate capital on acceptable terms; geographic concentration of our operations; levels of competition; the successful execution of our internal performance plans, including restructuring and cost reduction initiatives; the prices and availability of supply chain inputs, including raw materials, labor and home components; oil and other energy prices; the effects of U.S. trade policies, including the imposition of tariffs and duties on homebuilding products and retaliatory measures taken by other countries; the effects of weather, including the occurrence of drought conditions in parts of the western United States; the risk of loss from earthquakes, volcanoes, fires, floods, droughts, windstorms, hurricanes, pest infestations and other natural disasters, and the risk of delays, reduced consumer demand, and shortages and price increases in labor or materials associated with such natural disasters; the risk of loss from acts of war, terrorism, civil unrest or public health emergencies, including outbreaks of contagious disease, such as COVID-19; transportation costs; federal and state tax policies; the effects of land use, environment and other governmental laws and regulations; legal proceedings or disputes and the adequacy of reserves; risks relating to any unforeseen changes to or effects on liabilities, future capital expenditures, revenues, expenses, earnings, synergies, indebtedness, financial condition, losses and future prospects; changes in accounting principles; risks related to unauthorized access to our computer systems, theft of our homebuyers’ confidential information or other forms of cyber-attack; and additional factors discussed under the sections captioned “Risk Factors” included in our annual and quarterly reports filed with the Securities and Exchange Commission. The foregoing list is not exhaustive. New risk factors may emerge from time to time and it is not possible for management to predict all such risk factors or to assess the impact of such risk factors on our business. Investor Relations Contact: InvestorRelations@TriPointeHomes.com, 949-478-8696 Media Contact: Carol Ruiz, cruiz@newgroundco.com, 310-437-0045MENLO PARK, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Sight Sciences , Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced the results of a Budget Impact Analysis (“BIA”) of the TearCare ® System (“TearCare”) for the treatment of MGD-associated dry eye disease (“DED”) in the United States. A BIA estimates the fiscal impact of adopting a new technology or treatment within a specific provider environment or patient population – in this case, identifying the health savings associated with increased adoption of TearCare as compared to prescription dry eye medications for patients with DED.* The analysis, projected over a two-year period, focused on moderate to severe MGD- associated DED in U.S. patients over 18 years of age. It compared the financial impact of TearCare to commonly prescribed dry eye medications, including Restasis 0.05% branded and generic, and Xiidra 5%. Key findings indicated that a 20% increase in market share of TearCare compared to prescription dry eye medications would yield an estimated annual savings of $36.87 per member per year (“PMPY”) in a hypothetical health plan with one million covered lives. The study showed a direct relationship between increased utilization of TearCare in place of prescription medications and total costs savings from a US payer perspective. “In addition to the strong clinical efficacy of TearCare shown in the SAHARA and OLYMPIA randomized controlled trials, this budget impact analysis reported that increased adoption of TearCare treatments for patients with MGD-associated DED was estimated to result in meaningful cost savings. We believe the combination of the strong clinical data from the SAHARA RCT and the findings of this budget impact analysis create a compelling case for payors to cover treatments performed with TearCare at an appropriate reimbursement level,” said Paul Badawi, Co-Founder and Chief Executive Officer of Sight Sciences. “Pioneering market access to interventional dry eye treatments with TearCare on behalf of patients and the eye care providers who care for them is a core component of our strategy and this milestone represents progress towards delivering this innovative technology to a portion of the 17.9 million patients diagnosed with dry eye disease in the U.S.” Authors and affiliations : Phoenix Riley, PharmD, MSc (AESARA, Inc.); Cristina Masseria, PhD (AESARA, Inc.); Chad Patel, PharmD (AESARA, Inc.); Roberta Longo, PhD (AESARA, Inc.); Lorie Mody, PharmD (AESARA, Inc.), and Thomas Chester, OD, FAAO (Cleveland Eye Clinic). *The BIA was developed in accordance with established ISPOR guidelines, but it was based upon various assumptions, including with respect to cost of treatments, respective usage and market uptake of prescription drops and TearCare, efficacy (including duration of effect), safety and similar factors. These assumptions may not be consistent with actual clinical and market conditions, and changes in one or more of these assumptions could cause individual health plan results to differ. Paper Reference: Chester, T., Longo, R., Masseria, C., Riley, P., Patel, C., & Mody, L. (2024). Budget impact analysis (BIA) of the TearCare System for the treatment of meibomian gland dysfunction (MGD)-associated dry eye disease (DED) in the United States (US). Expert Review of Ophthalmology , DOI: 10.1080/17469899.2024.2444930. About Sight Sciences Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI ® Surgical System is an implant-free glaucoma surgery technology (i) indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and (ii) CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world’s leading cause of irreversible blindness. The Company’s SION ® Surgical Instrument is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s TearCare System technology is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to Meibomian Gland Disease (“MGD”) when used in conjunction with manual expression of the meibomian glands, enabling clearance of gland obstructions by eyecare providers to address the leading cause of dry eye disease. For more information, visit www.sightsciences.com . Sight Sciences, the Sight Sciences logo, TearCare, SmartHub and SmartLids are trademarks of Sight Sciences registered in the United States. OMNI and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories. © 2024 Sight Sciences. All rights reserved. Forward-Looking Statements This press release, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and includes this statement for purposes of complying with these safe harbor provisions. Any statements made in this press release that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include, without limitation statements regarding estimated costs savings associated with use of the TearCare System; and the belief that the findings of this budget impact analysis create a compelling case for payors to cover treatments performed with TearCare at an appropriate reimbursement level. These statements often include words such as “anticipate,” “expect,” “suggests,” “plan,” “believe,” “intend,” “estimates,” “targets,” “projects,” “should,” “could,” “would,” “may,” “will,” “forecast” and other similar expressions. We base these forward-looking statements on our current expectations, plans and assumptions that we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances at such time. Although we believe that these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our business, results of operations and financial condition and could cause actual results to differ materially from those expressed in the forward-looking statements. These forward-looking statements are subject to and involve numerous risks, uncertainties and assumptions, including those discussed under the caption “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, as may be updated from time to time in subsequent filings, and you should not place undue reliance on these statements. These cautionary statements are made only as of the date of this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Media contact pr@SightSciences.com Investor contact: Philip Taylor Gilmartin Group 415.937.5406 Investor.Relations@Sightsciences.com

Noel Gallagher reveals his mum Peggy’s hilarious reaction to news of Oasis getting back together

Rangers 1-1 Tottenham: Dejan Kulusevski earns Spurs a point in Europa League battleWashington, Dec 19 (AP) The Senate passed a defence bill on Wednesday that authorises significant pay raises for junior enlisted service members, aims to counter China's growing power and boosts overall military spending to USD 895 billion while also stripping coverage of transgender medical treatments for children of military members. The annual defence authorisation bill usually gains strong bipartisan support and has not failed to pass Congress in nearly six decades, but the Pentagon policy measure in recent years has become a battleground for cultural issues. Republicans this year sought to tack on to the legislation priorities for social conservatives, contributing to a months-long negotiation over the bill and a falloff in support from Democrats. Also Read | Cyclone Chido: Tropical Cyclone Kills 13, Affects Over 45,000 in Malawi. Still, the bill passed comfortably 85-14, sending it to President Joe Biden. Eleven senators who caucus with Democrats, as well as three Republicans, voted against the legislation. The bill "isn't perfect, but it still includes some very good things that Democrats fought for", said Senate Majority Leader Chuck Schumer, D-NY, in a floor speech. "It has strong provisions to stand up against the Chinese Communist Party here on a national security basis." Also Read | Nigeria Stampede: Several Children Killed During Stampede at Holiday Fair Event in Basorun, Oyo State Governor Says (Watch Video). In the House, a majority of Democrats voted against the bill last week after House Speaker Mike Johnson insisted on adding the provision to ban the military health system from providing transgender medical care for children. The legislation easily passed by a vote of 281-140. Senate Republican leaders argued that its 1 per cent increase for defence spending was not enough, especially at a time of global unrest and challenges to American dominance. Senate Republicans had argued for a generational boost to defence spending this year, but are planning another push for more defence funding once they control the White House and Congress next year. "We are currently experiencing the most dangerous national security moments since World War II," said Republican Senator Roger Wicker, who will chair the Senate Armed Services Committee next year. He has pushed for larger boosts to defence funding that would break spending caps that were agreed to in the bipartisan deal to suspend the nation's debt ceiling last year. The annual defence authorisation bill directs key Pentagon policy, but it would still need to be backed up with an appropriations package. Senate Republican leader Mitch McConnell of Kentucky said in a floor speech this week that without the topline increase, "major bill provisions like a pay raise for enlisted service members will come at the expense of investments in the critical weapons systems and munitions that deter conflict and keep them safe". The legislation provides for a 14.5 per cent pay raise for junior enlisted service members and a 4.5 per cent increase for others. Lawmakers said those were key to improving the quality of life of service members at a time when many military families rely on food banks and other government assistance programmes to make ends meet. "It includes major quality of life improvements, enhancing things like childcare, housing, medical services, employment support for military spouses and much more," said Senator Jack Reed, D-RI, who chairs the Senate Armed Services Committee. The legislation also directs resources towards a more confrontational approach to China, including establishing a fund that could be used to send military resources to Taiwan in much the same way that the US has backed Ukraine. It also invests in new military technologies, including artificial intelligence, and bolsters the US production of ammunition. The US has also moved in recent years to ban the military from purchasing Chinese products, and the defence bill extended that with prohibitions on Chinese goods from garlic in military commissaries to drone technology. The Chinese foreign ministry responded to that move last week by calling the bans laughable. "I do not think it could ever occur to garlic that it would pose a major threat to the US," said Mao Ning, a ministry spokeswoman. "From drones to cranes, from refrigerators to garlic, more and more Chinese-made products have been accused by the US of posing national security risks. But has the US shown any reliable evidence or rationale to back up those accusations?" But in Congress, Republican and Democratic lawmakers have been mostly united in their stance that China is a rising threat. Instead, it was culture war issues that divided lawmakers on the bill, which took months to negotiate. The Republican-controlled House had passed a version of the bill in June that would have banned the Defence Department's policy of reimbursing costs for service members who travel to another state for an abortion, ended gender affirming care for transgender troops and weeded out diversity initiatives in the military. Most of those provisions did not make it into the final package, though Republicans are expecting Donald Trump to make sweeping changes to Pentagon policy when he enters office in January. The bill also still prohibits funding for teaching critical race theory in the military and prohibits TRICARE health plans from covering gender dysphoria treatment for children under 18 if that treatment could result in "sterilisation". (AP) (This is an unedited and auto-generated story from Syndicated News feed, LatestLY Staff may not have modified or edited the content body)Thrivent Financial for Lutherans Has $1.73 Million Stake in American Airlines Group Inc. (NASDAQ:AAL)